Five-Year Outcomes with Anti-Vascular Endothelial Growth Factor Treatment of Neovascular Age-Related Macular Degeneration: The Comparison of Age-Related Macular Degeneration Treatments Trials.

ABSTRACT:

Purpose

To describe outcomes 5 years after initiating treatment with bevacizumab or ranibizumab for neovascular age-related macular degeneration (AMD).

Design

Cohort study.

Participants

Patients enrolled in the Comparison of AMD Treatments Trials.

Methods

Patients were assigned randomly to ranibizumab or bevacizumab and to 1 of 3 dosing regimens. After 2 years, patients were released from the clinical trial protocol. At 5 years, patients were recalled for examination.

Main outcome measures

Visual acuity (VA) and morphologic retinal features.

Results

Visual acuity was obtained for 647 of 914 (71%) living patients with average follow-up of 5.5 years. The mean number of examinations for AMD care after the clinical trial ended was 25.3, and the mean n

SUBMITTER: Comparison of Age-related Macular Degeneration Treatments Trials (CATT) Research Group 

PROVIDER: S-EPMC4958614 | biostudies-literature | 2016 Aug

REPOSITORIES: biostudies-literature